Male breast cancer: A retrospective review of clinical profile from a tertiary cancer care center of India

Ram, Dharma; Rajappa, Suhas Kodasoge; Selvakumar, Veda Padma Priya; Shukla, Himanshu; Goel, Ashish; Kumar, Rajeev; Kumar, Kapil

doi:10.4103/sajc.sajc_2_17

Cited by 10 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infiltrating ductal carcinoma (IDC) is the commonest histopathological type reported in most of the Indian MBC studies. [8][9][10][11][12][13][14][15][16] This is similar to findings in Western studies too. 18,21,24,25 Other histologies like lobular carcinoma, medullary carcinoma, papillomas, Pagets' disease, and inflammatory breast carcinoma are relatively rare.…”

Section: Histologysupporting

confidence: 86%

“…18 The median age of MBC in Indian studies is 5-10 years younger than that reported in western literature. [8][9][10][11][12][13][14][15][16][17] In our study, also the median age was 58 years with an age range of 36-76 years. This is almost a decade earlier than what is being reported in the West.…”

Section: Agementioning

confidence: 87%

“…7 The number of patients ranged from 18 to 106. [8][9][10][11][12][13][14][15][16] The reported incidence of MBC is around 0.5-2.8% of all breast cancers in these institutes. 8,10,12,14 The incidence of MBC in our series is 1.1% which is consistent with Indian data but slightly higher in comparison to global incidence.…”

Section: Incidencementioning

confidence: 99%

“…As per Indian data majority of patients present in stage III. [8][9][10][11][12][13][14][15][16] Few recent Indian studies have reported majority patients in stage II at presentation. 15,16 However, most of the patients in our study presented in advanced stage of disease.…”

Section: Stage At Presentationmentioning

confidence: 99%

See 3 more Smart Citations

Male breast cancer: a 5-year experience from a State Cancer Institute

et al. 2021

View full text Add to dashboard Cite

Background: Male breast cancer (MBC) is an uncommon malignancy accounting for <1% of all cancers in men and <1 % of overall breast cancer cases. Although there are many similarities between MBC and female breast cancer (FBC), they are not identical in clinical behaviour. There is need to understand the exact biological behavior of MBC.Methods: A retrospective observational study was done at State Cancer Institute, IGIMS, Patna which included all MBC patients registered during a 5-year study period (January 2016 to April 2021). 16 consecutive cases of MBC were identified and their detailed clinicopathological profile was analyzed.Results: MBC accounted for 1.10% of the total breast cancer cases. The median age of presentation was 58 years. Most common presentation was lump. Invasive ductal carcinoma (IDC) was most common histology. Majority of the patient presented to us in advanced stage. Estrogen receptor (ER)/progesterone receptor (PR) status was found to be positive in 12 patients. HER-2/neu receptor was positive in 4 patients. 2 patients had triple negative disease (TNBC) status. Surgery in the form of modified radical mastectomy (MRM) was done in 10 patients. All patients received adjuvant therapy as per NCCN guidelines.Conclusions: MBC is rare disease presenting at a relatively early age in Indian male patients. Most of them have positive ER/PR status. As outcomes have not improved comparatively, there is a need to evolve separate guidelines for MBC.

show abstract

Section: Histologysupporting

confidence: 86%

Section: Agementioning

confidence: 87%

Section: Incidencementioning

confidence: 99%

Section: Stage At Presentationmentioning

confidence: 99%

See 2 more Smart Citations

Male breast cancer: a 5-year experience from a State Cancer Institute

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Shah et al (6), in their review of 42 male breast cancers found 83.3% to have IDC and 89.7% to be hormone receptor positive. Likewise, D Ram et al (7) in their analysis of 27 men, observed that 85.2% of them presented with IDC and 77.8% with hormone positive tumors. In an analysis of 2992 male patients from the SEER program, Leone et al (8).…”

Section: Discussionmentioning

confidence: 87%

Survival Outcomes in Male Breast Cancer – A Single Institution Experience

Hariharan

2018

Asian Pac J Cancer Care

View full text Add to dashboard Cite

Introduction: Male breast cancer is an uncommon entity. Due to the scarce numbers, treatment protocolshave largely been extrapolated from available evidence for female breast cancers.Methods: We analysed the clinicopathological features and survival outcomes for male breast cancer patients treated at our institute between January 2010 and June 2016.Results: Of the 5534 women treated at our institute, we screened 40 male breast cancers of whom 33 had available follow up data and were included in the present analysis. Male breast cancer constituted 0.7% of all breast cancers. The median age was 60 years and the median tumor size was 3cm with 66% of patients having nodal disease at presentation. Invasive ductal carcinoma was the most common histology and 97% were hormone receptor positive. Most of the patients (87.8%) underwent an upfront modified radical mastectomy. With a median follow up of 36 months, 10 patients experienced recurrences all of which were distant metastasis (3 to the bone, 1 to the brain, and 6 had visceral metastasis). Of these, 7 patients succumbed to the disease. The 3-year overall survival was 78.7 %.Conclusion: Male breast cancer is a rare clinical entity and current treatment guidelines follow those for women. Due to the lack of awareness, men often present to clinics at an advanced stage. Social support targeted at improving awareness and access to treatment could improve outcomes in this cohort.

show abstract